FDA announces new network to focus exclusively on patients

April 29, 2013
FDA announces new network to focus exclusively on patients
The U.S. Food and Drug Administration has announced the launch of a new interactive tool for educating patients, their advocates, and consumers about the processes involved in medication development.

(HealthDay)—The U.S. Food and Drug Administration has announced the launch of a new interactive tool for educating patients, their advocates, and consumers about the processes involved in medication development.

Since the early 1990s, the FDA has been working directly with patients and their advocates to help them understand about product development and regulation. This includes patient representatives who participate in FDA advisory meetings. Patient input will be more focused and valuable when they better understand how are studied, reviewed, assessed, and brought to market.

The interactive FDA Patient Network website educates patients, their advocates, and consumers about the development of prescription and over-the-counter medications. New channels of communication will be available, including live chats with senior agency officials. With the launch of this website and the increased ability for patients to understand the safety processes involved in drug development, it is hoped that the role of patients can be expanded to a wider audience in new and broader ways.

"I am excited because this new Patient Network website provides a for FDA to follow in making its inner workings transparent to the public," Margaret A. Hamburg, M.D., Commissioner of the FDA, said in a statement. "It ushers in a new era of access and input for patients and consumers that will evolve with the needs of both communities."

Explore further: FDA: Draft guidance issued on abuse-deterrent opioids

More information: More Information

Related Stories

FDA: Draft guidance issued on abuse-deterrent opioids

January 10, 2013
(HealthDay)—The U.S. Food and Drug Administration has issued a draft guidance document to assist the pharmaceutical industry in developing new formulations of opioid drugs with abuse-deterrent properties.

FDA weighs over-the-counter switch for key drugs

March 8, 2012
Some of the most widely used prescription drugs, including those to treat cholesterol and high blood pressure, could be available over the counter under a new proposal being weighed by government regulators.

FDA Commissioner: budget cuts mean less safe food

February 28, 2013
Food and Drug Administration Commissioner Margaret Hamburg says the lack of a new 2013 budget from Congress and the upcoming across-the-board spending cuts will mean fewer food safety inspections and an increased risk to ...

Recommended for you

Patients receive most opioids at the doctor's office, not the ER

January 16, 2018
Around the country, state legislatures and hospitals have tightened emergency room prescribing guidelines for opioids to curb the addiction epidemic, but a new USC study shows that approach diverts attention from the main ...

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

Price tag on gene therapy for rare form of blindness: $850K

January 3, 2018
A first-of-its kind genetic treatment for blindness will cost $850,000 per patient, making it one of the most expensive medicines in the world and raising questions about the affordability of a coming wave of similar gene-targeting ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.